Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)

Principal Investigator

Andrew Brenner, MD, PhD, is a professor of medicine in the Division of Hematology and Oncology at The University of Texas Health Science Center at San Antonio, specializing in breast cancer and brain and spinal cord cancers. He is internationally acclaimed for advancing novel therapies to treat breast cancers and central nervous system tumors, alongside his active clinical practice.

About this study

ReSPECT-GBM is an FDA-approved Phase 2 clinical trial sponsored by Plus Therapeutics, Inc. and is supported by the U.S. National Institutes of Health. The objective is to determine the safety and efficacy of a single administration of a new targeted radiation therapy, Rhenium (Re186) Obisbemeda, in adult patients diagnosed with recurrent glioblastoma.

The Phase 2 clinical study involves placing a catheter into the tumor during a needle biopsy. The following day, patients receive an infusion of the radiation-containing particles directly through the catheter into the tumor. The catheter is then removed on the third day, and patients are discharged home for outpatient follow-up. 

The U.S. Food and Drug Administration (FDA) has not approved 186RNL for this specific disease as it remains an investigational treatment.

NATIONAL TRIAL REFERENCE NUMBER | NCT01906385

When speaking with your physician, please have the national trial reference number available.

Learn more about this clinical trial

Participation eligibility

Researchers look for people who fit a certain description, which is called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

To qualify

• Must be age 18 or older
• Have recurrent glioblastoma after previously receiving radiation and chemotherapy
• Be able to undergo an MRI scan
• Have not taken Avastin medication in the past

Learn more about additional participation criteria